bronchodilators
Can worm drugs open airways via TMEM16A?
Open access · cc by · source: Europe PMC
A >500k-compound screen found niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways and resist pathways that blunt β-agonists.
Key findings
~40% of severe asthma patients respond poorly to β-agonists. Niclosamide and nitazoxanide blocked TMEM16A and provided robust bronchodilation, offering a complementary mechanism for poorly controlled asthma/COPD.
Methodology
Screened over half a million compounds for TMEM16A antagonism, characterized niclosamide/nitazoxanide pharmacology, and tested bronchodilation in mouse tracheal rings and human small airways under harsh contractile/inflammatory conditions.
Limitations
In vitro/ex vivo potency is not the same as proven clinical asthma benefit; safety/dosing for inhaled or systemic airway use needs dedicated trials.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Not yet placed on a claim. This paper has study layers, but no concept page yet cites it as support, challenge, or qualifier.
Related papers in this topic
Same topic cluster — not a recommendation engine.